

# Yanina Jansen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6378280/publications.pdf>

Version: 2024-02-01

33  
papers

987  
citations

686830

13  
h-index

476904

29  
g-index

33  
all docs

33  
docs citations

33  
times ranked

1890  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Comprehensive Review on the Surgical Aspect of Lung Transplant Models in Mice and Rats. <i>Cells</i> , 2022, 11, 480.	1.8	3
2	A Focused Review on Primary Graft Dysfunction after Clinical Lung Transplantation: A Multilevel Syndrome. <i>Cells</i> , 2022, 11, 745.	1.8	5
3	Anti-PD-1: When to Stop Treatment. <i>Current Oncology Reports</i> , 2022, 24, 905-915.	1.8	5
4	Whole-Body MRI for the Detection of Recurrence in Melanoma Patients at High Risk of Relapse. <i>Cancers</i> , 2021, 13, 442.	1.7	7
5	A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab. <i>Cancers</i> , 2021, 13, 168.	1.7	24
6	Internal herniation through the foramen of Winslow: a case report. <i>Acta Chirurgica Belgica</i> , 2020, 120, 136-138.	0.2	2
7	Pembrolizumab for the treatment of uveal melanoma: A case series. <i>Rare Tumors</i> , 2020, 12, 203636132097198.	0.3	8
8	A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2589-2598.	2.0	44
9	Phase I clinical trial of decitabine (5-aza-2'-deoxycytidine) administered by hepatic arterial infusion in patients with unresectable liver-predominant metastases. <i>ESMO Open</i> , 2019, 4, e000464.	2.0	21
10	Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy. <i>Journal of Translational Medicine</i> , 2019, 17, 303.	1.8	89
11	Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. <i>Annals of Oncology</i> , 2019, 30, 1154-1161.	0.6	170
12	Successful treatment with intralesional talimogene laherparepvec in two patients with immune checkpoint inhibitor-refractory, advanced-stage melanoma. <i>Melanoma Research</i> , 2019, 29, 85-88.	0.6	15
13	A sequential dual cohort phase II clinical trial on adjuvant low-dose nivolumab with or without low-dose ipilimumab as adjuvant therapy following the resection of melanoma macrometastases (MM).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9585-9585.	0.8	5
14	Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy. <i>Melanoma Research</i> , 2018, 28, 65-70.	0.6	18
15	Baseline total metabolic tumor volume assessed by 18FDG-PET/CT predicts outcome in advanced melanoma patients treated with pembrolizumab. <i>Annals of Oncology</i> , 2018, 29, x7.	0.6	3
16	Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial. <i>Lancet Oncology</i> , The, 2017, 18, 464-472.	5.1	139
17	Real life outcome of advanced melanoma patients who discontinue pembrolizumab (PEMBRO) in the absence of disease progression.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9539-9539.	0.8	4
18	Whole-body MRI (WB MRI) including diffusion weighted (DW) imaging for the surveillance of melanoma patients at high risk for recurrence following surgery or systemic therapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, e21072-e21072.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Immune cell profiling of melanoma metastases from patients treated with TriMixDC-MEL dendritic cell therapy in combination with ipilimumab.. Journal of Clinical Oncology, 2017, 35, e21030-e21030.	0.8	0
20	Applications for quantitative measurement of BRAF V600 mutant cell-free tumor DNA in the plasma of patients with metastatic melanoma. Melanoma Research, 2016, 26, 157-163.	0.6	16
21	Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients. Journal of Translational Medicine, 2016, 14, 232.	1.8	27
22	Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4431-4439.	1.8	187
23	COMBI-rechallenge: a phase II clinical trial on dabrafenib plus trametinib in BRAFV600-mutant melanoma patients who previously experienced progression on BRAF(+MEK)-inhibition. Annals of Oncology, 2016, 27, vi389.	0.6	2
24	Correlation between baseline characteristics and clinical outcome of patients with advanced melanoma treated with pembrolizumab (PEMBRO). Annals of Oncology, 2016, 27, vi386.	0.6	5
25	Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors. Journal of Translational Medicine, 2016, 14, 95.	1.8	117
26	Single-center "real life experience" with pembrolizumab (PEMBRO) in pretreated advanced melanoma patients.. Journal of Clinical Oncology, 2016, 34, e21049-e21049.	0.8	4
27	Correlation between baseline characteristics and clinical outcome of patients with pretreated advanced melanoma who received pembrolizumab (PEMBRO) in an expanded access program (EAP).. Journal of Clinical Oncology, 2016, 34, e21058-e21058.	0.8	0
28	Abstract B003: A randomized controlled phase II clinical trial on mRNA electroporated autologous dendritic cells for stage III/IV melanoma patients who are disease-free following the local treatment of macrometastases. , 2016, , .		0
29	3328 A randomized controlled phase II clinical trial on autologous monocyte-derived mRNA electroporated dendritic cells for stage III/IV melanoma patients who are disease-free following the local treatment of macrometastases. European Journal of Cancer, 2015, 51, S673.	1.3	2
30	Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib. Melanoma Research, 2015, 25, 550-554.	0.6	39
31	A Case Report of Long-Term Survival following Hepatic Arterial Infusion of L-Folinic Acid Modulated 5-Fluorouracil Combined with Intravenous Irinotecan and Cetuximab Followed by Hepatectomy in a Patient with Initially Unresectable Colorectal Liver Metastases. Case Reports in Oncological Medicine, 2015. 2015. 1-5.	0.2	2
32	Objective responses can be obtained by CTLA-4 inhibition in metastatic melanoma after BRAF inhibitor failure. Melanoma Research, 2015, 25, 68-74.	0.6	11
33	Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma. Melanoma Research, 2015, 25, 180-183.	0.6	13